|
Compound class:
Antibody
Comment: IGN523 is a humanized anti-CD98 (SLC3A2) monoclonal antibody being investigated as a potential therapy for acute myeloid leukemia (AML) [1-2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| A single Phase 1 clinical trial (NCT02040506) is assessing IGN523 in patients with relapsed or refractory AML. |
| Mechanism Of Action and Pharmacodynamic Effects |
| CD98 (SLC3A2) forms a functional amino acid transporter in association with the L-type amino acid transporter 1 (LAT1, SLC7A5). Amino acid transport in to these cells is essential for cell survival. Approximately 90% of AML cells express high levels of CD98 making this proetin a promising target for AML treatment. Antibody blocking of CD98 function directs the cells towards the apoptotic pathway and makes them vulnerable to natural killer cell destruction [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02040506 | A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML | Phase 1 Interventional | Igenica Biotherapeutics, Inc. | ||
